AIDS-related insulin resistance and lipodystrophy syndrome.

Tomoshige Kino, George P. Chrousos

Research output: Contribution to journalReview article

14 Citations (Scopus)


The recent development of highly active antiretroviral therapy (HAART) has drastically improved the life expectancy of AIDS patients, by reducing infection-related mortality. However, the prolongation of the lives of HIV-1-infected patients and/or the long-term use of novel, potent antiviral agents have generated a score of new problems and complications. Among them is the AIDS-related insulin resistance and lipodystrophy syndrome, which is observed in 30-80% of AIDS patients who are well controlled by HAART. This syndrome is associated with severe metabolic disturbances, such as carbohydrate intolerance/diabetes mellitus and dyslipidemia, which cause atherosclerotic cardiovascular disease. The etiology of this syndrome appears to be multi-factorial; other than the anti-viral drugs, hypercytokinemia and the HIV-1 infection itself, including the virally encoded molecules Vpr and Tat, could contribute to the development of these pathologic changes or increase the vulnerability of patients to the adverse effect of the therapeutic compounds. In this article, we review our current understanding of the pathogenesis and therapeutic approach of this newly emerging AIDS-associated metabolic syndrome.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalCurrent drug targets. Immune, endocrine and metabolic disorders
Issue number2
Publication statusPublished - Jun 2003
Externally publishedYes


ASJC Scopus subject areas

  • Immunology and Allergy
  • Endocrinology, Diabetes and Metabolism

Cite this